A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer

Silverio Tomao, Adriana Romiti, Federica Tomao, Marisa di Seri, Giuliana Caprio, Gian Paolo Spinelli, Edmondo Terzoli, Luigi Frati

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Many emerging new drugs have recently been trialled for treatment of early and advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role, mostly in patients with relapsed and metastatic disease after failure of chemotherapy with antracyclines. Methods: A phase II study was started in order to evaluate the activity and toxicity of a combination of paclitaxel and gemcitabine in a biweekly schedule on metastatic breast cancer patients previously treated with antracyclines. Results: Twenty-five patients received paclitaxel (150 mg/mq) by 3-hours infusion, followed by gemcitabine (2000 mg/mq) given as a 60 min i.v. infusion (day 1-14) for a maximum of eight cycles. In all patients treatment was evaluated for toxicity and efficacy; four patients (16%) achieved a complete response, 12 (48%) a partial response giving an overall objective response rate of 64%. Stable disease was documented in 5 patients (20%) and progressive disease occurred in 4 patients (16%). Conclusion: The schedule of treatment was safe and tolerable from a haematological and nonhaermatological point of view. These data confirm that the combination of gemcitabine and paclitaxel on a biweekly basis is an effective and well-tolerated regimen in breast cancer patients with prior therapeutic exposure to antracyclines.

Original languageEnglish
Article number137
JournalBMC Cancer
Volume6
DOIs
Publication statusPublished - May 24 2006

Fingerprint

gemcitabine
Paclitaxel
Breast Neoplasms
Appointments and Schedules
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. / Tomao, Silverio; Romiti, Adriana; Tomao, Federica; di Seri, Marisa; Caprio, Giuliana; Spinelli, Gian Paolo; Terzoli, Edmondo; Frati, Luigi.

In: BMC Cancer, Vol. 6, 137, 24.05.2006.

Research output: Contribution to journalArticle

Tomao, Silverio ; Romiti, Adriana ; Tomao, Federica ; di Seri, Marisa ; Caprio, Giuliana ; Spinelli, Gian Paolo ; Terzoli, Edmondo ; Frati, Luigi. / A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer. In: BMC Cancer. 2006 ; Vol. 6.
@article{aebe02d59ec24bb0aebe275695aaafa8,
title = "A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer",
abstract = "Background: Many emerging new drugs have recently been trialled for treatment of early and advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role, mostly in patients with relapsed and metastatic disease after failure of chemotherapy with antracyclines. Methods: A phase II study was started in order to evaluate the activity and toxicity of a combination of paclitaxel and gemcitabine in a biweekly schedule on metastatic breast cancer patients previously treated with antracyclines. Results: Twenty-five patients received paclitaxel (150 mg/mq) by 3-hours infusion, followed by gemcitabine (2000 mg/mq) given as a 60 min i.v. infusion (day 1-14) for a maximum of eight cycles. In all patients treatment was evaluated for toxicity and efficacy; four patients (16{\%}) achieved a complete response, 12 (48{\%}) a partial response giving an overall objective response rate of 64{\%}. Stable disease was documented in 5 patients (20{\%}) and progressive disease occurred in 4 patients (16{\%}). Conclusion: The schedule of treatment was safe and tolerable from a haematological and nonhaermatological point of view. These data confirm that the combination of gemcitabine and paclitaxel on a biweekly basis is an effective and well-tolerated regimen in breast cancer patients with prior therapeutic exposure to antracyclines.",
author = "Silverio Tomao and Adriana Romiti and Federica Tomao and {di Seri}, Marisa and Giuliana Caprio and Spinelli, {Gian Paolo} and Edmondo Terzoli and Luigi Frati",
year = "2006",
month = "5",
day = "24",
doi = "10.1186/1471-2407-6-137",
language = "English",
volume = "6",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer

AU - Tomao, Silverio

AU - Romiti, Adriana

AU - Tomao, Federica

AU - di Seri, Marisa

AU - Caprio, Giuliana

AU - Spinelli, Gian Paolo

AU - Terzoli, Edmondo

AU - Frati, Luigi

PY - 2006/5/24

Y1 - 2006/5/24

N2 - Background: Many emerging new drugs have recently been trialled for treatment of early and advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role, mostly in patients with relapsed and metastatic disease after failure of chemotherapy with antracyclines. Methods: A phase II study was started in order to evaluate the activity and toxicity of a combination of paclitaxel and gemcitabine in a biweekly schedule on metastatic breast cancer patients previously treated with antracyclines. Results: Twenty-five patients received paclitaxel (150 mg/mq) by 3-hours infusion, followed by gemcitabine (2000 mg/mq) given as a 60 min i.v. infusion (day 1-14) for a maximum of eight cycles. In all patients treatment was evaluated for toxicity and efficacy; four patients (16%) achieved a complete response, 12 (48%) a partial response giving an overall objective response rate of 64%. Stable disease was documented in 5 patients (20%) and progressive disease occurred in 4 patients (16%). Conclusion: The schedule of treatment was safe and tolerable from a haematological and nonhaermatological point of view. These data confirm that the combination of gemcitabine and paclitaxel on a biweekly basis is an effective and well-tolerated regimen in breast cancer patients with prior therapeutic exposure to antracyclines.

AB - Background: Many emerging new drugs have recently been trialled for treatment of early and advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role, mostly in patients with relapsed and metastatic disease after failure of chemotherapy with antracyclines. Methods: A phase II study was started in order to evaluate the activity and toxicity of a combination of paclitaxel and gemcitabine in a biweekly schedule on metastatic breast cancer patients previously treated with antracyclines. Results: Twenty-five patients received paclitaxel (150 mg/mq) by 3-hours infusion, followed by gemcitabine (2000 mg/mq) given as a 60 min i.v. infusion (day 1-14) for a maximum of eight cycles. In all patients treatment was evaluated for toxicity and efficacy; four patients (16%) achieved a complete response, 12 (48%) a partial response giving an overall objective response rate of 64%. Stable disease was documented in 5 patients (20%) and progressive disease occurred in 4 patients (16%). Conclusion: The schedule of treatment was safe and tolerable from a haematological and nonhaermatological point of view. These data confirm that the combination of gemcitabine and paclitaxel on a biweekly basis is an effective and well-tolerated regimen in breast cancer patients with prior therapeutic exposure to antracyclines.

UR - http://www.scopus.com/inward/record.url?scp=33745804491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745804491&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-6-137

DO - 10.1186/1471-2407-6-137

M3 - Article

VL - 6

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 137

ER -